Filing Details
Avalo Therapeutics, Inc. (NASDAQ:AVTX) filed a Form 8-K with the Securities and Exchange Commission on November 05, 2026, disclosing a material event.
8k filedNASDAQ:AVTX
Avalo Therapeutics, Inc. (AVTX) Reports Material Event to SEC
Avalo Therapeutics, Inc. (NASDAQ:AVTX) filed a Form 8-K with the Securities and Exchange Commission on November 05, 2026, disclosing a material event.
At publication ·
What changed
Avalo Therapeutics, Inc. (NASDAQ:AVTX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Avalo Therapeutics filed a Form 8-K with the SEC on November 5, 2026, disclosing a material event requiring shareholder awareness.
- The company's stock trades at $7.07 with a market capitalization of $220.3 million.
- Material events reported in 8-K filings include leadership changes, acquisitions, asset sales, or financial guidance modifications.
Market Context
Avalo Therapeutics, Inc.'s stock currently trades at $7.07 with a market capitalization of $220.3M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Avalo Therapeutics, Inc.'s stock.
All SEC filings for Avalo Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AVTX Stock Page
Frequently Asked Questions
Where can I read AVTX's SEC filings?
Browse all filings on our AVTX SEC filings page.
What types of SEC filings does Avalo Therapeutics, Inc. file?
Public companies like Avalo Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
